“…The expression differences of m 6 A-related genes, including ALKBH5, HNRNPC, METTL14, METTL3, YTHDF2, IGF2BP1, IGF2BP3, METTL16, RBMX, IGF2BP2, and HNRNPA2BA, were analyzed between the low-risk and the high-risk groups mentioned above in LUAD patients (Huang et al, 2020). (Tao et al, 2018;Ding et al, 2020;Wu et al, 2020), gracillin (Liu et al, 2021;Yang J. et al, 2021;, polyphyllin I (Chang et al, 2017;Tian et al, 2020;Lai et al, 2021;Shen et al, 2021), polyphyllin II (Niu et al, 2020), polyphyllin III (Zhou et al, 2021), polyphyllin VI (Liu et al, 2020;Teng et al, 2020), polyphyllin VII (He et al, 2020;Zhao et al, 2021) and polyphyllin H) were collected by using the online tools (Su et al, 2019), including PubChem (https://pubchem. The overlapping gene set between the drug targets of Chonglou active ingredients with the EMT-LUAD related genes were enquired in the STRING database (version 11.5) (EMT-LUAD- Frontiers in Genetics frontiersin.org Chonglou related genes), which was used for the following proteinprotein interactions (PPI) network, hub genes and enrichment analyses.…”